Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845799 | 0.93 | LCK (0.46) | LCKFYNMYCLRRK2KDM4E | |
| SCHEMBL2818164 | 0.86 | LCK (0.60) | LCKFYNMYCLRRK2KDM4E | |
| SCHEMBL11310945 | 0.85 | LCK (0.58) | LCKFYNMYCLRRK2KDM4E | |
| SCHEMBL10979402 | 0.85 | LCK (0.53) | LCKFYNMYCLRRK2KDM4E | |
| SCHEMBL6704966 | 0.82 | LCK (0.60) | LCKFYNMYCKDM4EMAPT | |
| SCHEMBL28625696 | 0.82 | LCK (0.55) | LCKFYNMYCKDM4EMAPT | |
| SCHEMBL6161597 | 0.81 | LCK (0.50) | LCKFYNLRRK2KDM4EMAPT | |
| SCHEMBL2730020 | 0.81 | ALDH1A1 (0.49) | LCKFYNLRRK2KDM4EMAPT | |
| SCHEMBL15795417 | 0.80 | LCK (0.62) | LCKFYNMYCLRRK2KDM4E | |
| SCHEMBL25304441 | 0.80 | PYGL (0.52) | LCKFYNMYCLRRK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-4083032-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021129584-A1 | PD-L1 ANTAGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | CD274, PDCD1LG2, PDCD1 | LCK 469/4885FYN 3199/4885MYC 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.